Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares Rose High After The Success Of Drug Hep C Print
By Josh Gee   
Monday, 22 December 2014 20:04

After the biotech reported that the NS5A drug of Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) combined with Gilead's Sovaldi scored a quick cure among a small group of hepatitis C patients after only 6 weeks of treatment, the shares of Achillion rose high.

Achillion shares went up more than 16% as company execs touted their "best-in-class" potential and analysts continued to assess the implications of AbbVie's FDA approval on Friday for its cocktail, Viekira Pak.

Since now Gilead and AbbVie have arrived in the market, analysts have begun focusing more on the next wave of therapies looking to compete on price and duration of treatment. Achillion attracted considerable attention with its 100% cure rate in a small 8-week study involving treatment naïve genotype 1 patients with ACH-3102 and Sovaldi last summer. In this new study a combination of the two therapies achieved a 100% cure rate among 12 patients after 6 weeks of therapy, where signs of the virus disappeared within 4 weeks of completing treatment. And that will help to raise the market expectations even more.

Achillion will be required to deal with a clinical hold, which is temporarily chilled red-hot rumor of a potential takeover. The hold, though, was lifted ahead of the early-stage data, and Merck helped to reignite the speculation of a possible takeover after paying $3.9 billion for the rival Idenix. Few biotechs loved to flirt with investors about the prospect of a buyout more than the hepatitis C specialist Achillion.

Dr. David Apelian, the chief medical officer at Achillion said that the data when combined with the Phase II proxy study results will lead them to believe that the doublet regimen of ACH-3102 and ACH-3422 can be a highly competitive, regimen to cure HCV.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!